D.A. Davidson & CO. Takes $516,000 Position in Exact Sciences Corporation (NASDAQ:EXAS)

D.A. Davidson & CO. bought a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 11,922 shares of the medical research company's stock, valued at approximately $516,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Exact Sciences by 74.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after buying an additional 2,462,165 shares during the last quarter. Capital World Investors increased its stake in Exact Sciences by 10.7% during the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after acquiring an additional 1,696,321 shares during the period. Mackenzie Financial Corp raised its holdings in Exact Sciences by 107.7% in the 4th quarter. Mackenzie Financial Corp now owns 2,919,325 shares of the medical research company's stock valued at $164,037,000 after acquiring an additional 1,513,873 shares in the last quarter. Norges Bank bought a new stake in shares of Exact Sciences in the 4th quarter worth approximately $50,625,000. Finally, T. Rowe Price Investment Management Inc. grew its holdings in shares of Exact Sciences by 25.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock worth $239,922,000 after purchasing an additional 876,985 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Wall Street Analysts Forecast Growth

EXAS has been the subject of a number of recent research reports. Royal Bank Of Canada upped their target price on Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Mizuho began coverage on shares of Exact Sciences in a report on Thursday, April 10th. They set an "outperform" rating and a $60.00 price objective for the company. Robert W. Baird lifted their target price on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. Barclays dropped their price target on shares of Exact Sciences from $75.00 to $65.00 and set an "overweight" rating for the company in a research report on Tuesday, June 24th. Finally, Guggenheim reaffirmed a "buy" rating and set a $60.00 price objective on shares of Exact Sciences in a report on Friday, April 11th. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $70.50.

Insider Transactions at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 3,207 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $53.20, for a total value of $170,612.40. Following the transaction, the director directly owned 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Exact Sciences Price Performance

NASDAQ EXAS traded up $2.39 on Monday, hitting $54.30. 2,235,268 shares of the company were exchanged, compared to its average volume of 2,577,853. Exact Sciences Corporation has a 1-year low of $39.97 and a 1-year high of $72.83. The firm has a 50 day moving average of $54.36 and a two-hundred day moving average of $50.97. The company has a current ratio of 2.73, a quick ratio of 2.38 and a debt-to-equity ratio of 0.97. The company has a market cap of $10.24 billion, a P/E ratio of -9.85, a P/E/G ratio of 11.08 and a beta of 0.95.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative net margin of 36.06% and a negative return on equity of 3.75%. The company had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same period in the previous year, the firm posted ($0.60) earnings per share. The company's revenue was up 10.9% on a year-over-year basis. On average, equities analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.